EA004049B1
(ru)
*
|
1998-11-10 |
2003-12-25 |
Янссен Фармацевтика Н.В. |
Пиримидины, ингибирующие репликацию вич
|
GB9914258D0
(en)
*
|
1999-06-18 |
1999-08-18 |
Celltech Therapeutics Ltd |
Chemical compounds
|
DE19945982A1
(de)
*
|
1999-09-24 |
2001-03-29 |
Knoll Ag |
Geschwindigkeitsbestimmte Partikel
|
PL207590B1
(pl)
*
|
1999-09-24 |
2011-01-31 |
Janssen Pharmaceutica Nv |
Cząstka stanowiąca dyspersję stałą oraz postać dawkowania, sposób ich otrzymywania i zastosowanie
|
AU770600B2
(en)
|
1999-10-07 |
2004-02-26 |
Amgen, Inc. |
Triazine kinase inhibitors
|
WO2001060816A1
(en)
|
2000-02-17 |
2001-08-23 |
Amgen Inc. |
Kinase inhibitors
|
AU782948B2
(en)
|
2000-05-08 |
2005-09-15 |
Janssen Pharmaceutica N.V. |
Prodrugs of HIV replication inhibiting pyrimidines
|
US7276510B2
(en)
*
|
2000-05-08 |
2007-10-02 |
Janssen Pharmaceutica, Inc. |
HIV replication inhibitors
|
WO2002037338A1
(en)
*
|
2000-11-01 |
2002-05-10 |
Snapnames.Com, Inc. |
Registry-integrated internet domain name acquisition system
|
US6958211B2
(en)
|
2001-08-08 |
2005-10-25 |
Tibotech Bvba |
Methods of assessing HIV integrase inhibitor therapy
|
US7638522B2
(en)
|
2001-08-13 |
2009-12-29 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
|
US8101629B2
(en)
|
2001-08-13 |
2012-01-24 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
|
JO3429B1
(ar)
|
2001-08-13 |
2019-10-20 |
Janssen Pharmaceutica Nv |
مشتقات برميدينات مثبطة فيروس الايدز
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
EP1453516A2
(de)
|
2001-10-17 |
2004-09-08 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren
|
EP2332924A1
(de)
|
2001-10-17 |
2011-06-15 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Pyrimidinderivate, Arzneimittel enthaltend diese Verbindungen, deren Verwendung und Verfahren zu ihrer Herstellung
|
IL161662A0
(en)
|
2001-11-01 |
2004-09-27 |
Janssen Pharmaceutica Nv |
Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors (gsk3 inhibitors)
|
HUP0402330A3
(en)
|
2001-11-01 |
2010-03-29 |
Janssen Pharmaceutica Nv |
Amide derivatives as glycogen synthase kinase 3-beta inhibitors, process for producing them, pharmaceutical compositions containing them and use thereof
|
SE0104140D0
(sv)
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
EP1485353B1
(de)
|
2002-03-13 |
2011-08-24 |
Janssen Pharmaceutica NV |
Histone-deacetylase-inhibitoren
|
MXPA04007776A
(es)
|
2002-03-13 |
2004-10-15 |
Janssen Pharmaceutica Nv |
Derivados de sulfonilamino como nuevos inhibidores de histona deacetilasa.
|
GB0206215D0
(en)
|
2002-03-15 |
2002-05-01 |
Novartis Ag |
Organic compounds
|
WO2003093344A1
(en)
*
|
2002-05-03 |
2003-11-13 |
Janssen Pharmaceutica N.V. |
Polymeric microemulsions
|
AR039540A1
(es)
*
|
2002-05-13 |
2005-02-23 |
Tibotec Pharm Ltd |
Compuestos microbicidas con contenido de pirimidina o triazina
|
TW200409629A
(en)
|
2002-06-27 |
2004-06-16 |
Bristol Myers Squibb Co |
2,4-disubstituted-pyridine N-oxides useful as HIV reverse transcriptase inhibitors
|
MXPA05001096A
(es)
|
2002-07-29 |
2005-11-23 |
Rigel Pharmaceuticals Inc |
Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
|
AU2003266413B2
(en)
*
|
2002-08-09 |
2009-04-02 |
Janssen Pharmaceutica N.V. |
Processes for the preparation of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
|
EP2422775A3
(de)
*
|
2002-09-20 |
2012-04-18 |
Alpharma, Inc. |
Sequestriermitteluntereinheit und zugehörige Zusammensetzungen und Verfahren
|
KR20050084027A
(ko)
*
|
2002-11-28 |
2005-08-26 |
쉐링 악티엔게젤샤프트 |
Chk-, pdk- 및 akt-억제성 피리미딘, 그의제조방법 및 약제로서의 그의 용도
|
EP1599468B1
(de)
|
2003-01-14 |
2007-10-03 |
Arena Pharmaceuticals, Inc. |
1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
|
MXPA05008364A
(es)
|
2003-02-07 |
2005-11-04 |
Janssen Pharmaceutica Nv |
Derivados de pirimidina para la prevencion de una infeccion por vih.
|
PL232814B1
(pl)
|
2003-02-07 |
2019-07-31 |
Janssen Pharmaceutica Nv |
Pochodne 1,2,4-triazynowe, ich zastosowanie i zawierająca je kompozycja farmaceutyczna
|
JP4634367B2
(ja)
|
2003-02-20 |
2011-02-16 |
スミスクライン ビーチャム コーポレーション |
ピリミジン化合物
|
CL2004000306A1
(es)
*
|
2003-02-20 |
2005-04-08 |
Tibotec Pharm Ltd |
Compuestos derivados de pirimidina sustituidas con indano; proceso para su preparacion; composicion farmaceutica que lo comprende; combinacion farmaceutica; y su uso para el tratamiento o profilaxis de una enfermedad infecciosa.
|
BRPI0412734A
(pt)
|
2003-07-17 |
2006-09-26 |
Tibotec Pharm Ltd |
processo para preparação de partìculas que contêm um antiviral
|
PL1656372T3
(pl)
|
2003-07-30 |
2013-08-30 |
Rigel Pharmaceuticals Inc |
Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym
|
AU2004274185B2
(en)
*
|
2003-09-25 |
2009-12-10 |
Janssen Pharmaceutica N.V. |
HIV replication inhibiting purine derivatives
|
US8099262B2
(en)
|
2004-03-02 |
2012-01-17 |
Virco Bvba |
Estimation of clinical cut-offs
|
EP1598343A1
(de)
*
|
2004-05-19 |
2005-11-23 |
Boehringer Ingelheim International GmbH |
2-Arylaminopyrimidine als PLK Inhibitoren
|
AP2336A
(en)
|
2004-07-28 |
2011-12-08 |
Janssen Pharmaceutica Nv |
Subsituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase.
|
WO2006015985A1
(en)
|
2004-08-10 |
2006-02-16 |
Janssen Pharmaceutica N.V. |
Hiv inhibiting 1,2,4-triazin-6-one derivatives
|
AU2005288866B2
(en)
|
2004-09-30 |
2012-07-26 |
Janssen Sciences Ireland Uc |
HIV inhibiting 5-substituted pyrimidines
|
ES2371923T3
(es)
|
2004-09-30 |
2012-01-11 |
Tibotec Pharmaceuticals |
5-heterociclil-pirimidinas que inhiben el vih.
|
WO2006035068A2
(en)
|
2004-09-30 |
2006-04-06 |
Tibotec Pharmaceuticals Ltd. |
Hiv inhibiting 5-carbo- or heterocyclic substituted pyrimidines
|
EP1807430B1
(de)
|
2004-10-29 |
2014-07-23 |
Janssen R&D Ireland |
Hiv-hemmende bicyclische pyrimidinderivative
|
US20060106043A1
(en)
*
|
2004-11-08 |
2006-05-18 |
Boehringer Ingelheim International Gmbh |
Method for treating HIV infection through co-administration of tipranavir and etravirine
|
US7557207B2
(en)
|
2004-11-24 |
2009-07-07 |
Rigel Pharmaceuticals, Inc. |
Spiro 2,4-pyrimidinediamine compounds and their uses
|
PT1856135E
(pt)
|
2005-01-19 |
2010-02-26 |
Rigel Pharmaceuticals Inc |
Pró-fármacos de compostos 2,4-pirimidinodiamina e suas utilizações
|
AU2006208778B2
(en)
*
|
2005-01-27 |
2012-08-09 |
Janssen Sciences Ireland Uc |
HIV inhibiting 2-( 4-cyanophenylamino) pyrimidine derivatives
|
DE602006001515D1
(de)
|
2005-02-16 |
2008-07-31 |
Astrazeneca Ab |
Chemische verbindungen
|
WO2006087387A1
(en)
*
|
2005-02-18 |
2006-08-24 |
Tibotec Pharmaceuticals Ltd. |
Hiv inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives
|
RS51435B
(en)
*
|
2005-03-04 |
2011-04-30 |
Tibotec Pharmaceuticals |
2- (4-CYANOPHENYL) -6-HYDROXYLAMINOPYRIMIDINE INHIBITING HIV
|
US20080287437A1
(en)
|
2005-05-16 |
2008-11-20 |
Astrazeneca Ab |
Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
|
ES2437202T3
(es)
*
|
2005-05-26 |
2014-01-09 |
Janssen R&D Ireland |
Procedimiento para preparar 4-[(1,6-dihidro-6-oxo-2-pirimidinil)-amino]benzonitrilo
|
KR101312225B1
(ko)
|
2005-06-08 |
2013-09-26 |
리겔 파마슈티칼스, 인크. |
Jak 경로의 억제를 위한 조성물 및 방법
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
AP2008004459A0
(en)
*
|
2005-10-06 |
2008-06-30 |
Univ Massachusetts |
Composition and sythesis of new reagents for inhibition of HIV replication
|
TW200800963A
(en)
|
2005-10-28 |
2008-01-01 |
Astrazeneca Ab |
Chemical compounds
|
CA2630717C
(en)
|
2006-01-19 |
2015-02-24 |
Janssen Pharmaceutica N.V. |
Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
|
DK1981874T3
(da)
|
2006-01-19 |
2009-09-28 |
Janssen Pharmactuica N V |
Aminophenylderivater som nye inhibitorer af histondeacetylase
|
EP1981875B1
(de)
|
2006-01-19 |
2014-04-16 |
Janssen Pharmaceutica N.V. |
Substituierte indolyl-amino-alkyl-derivate als histon-deacetylase-inhibitoren
|
ES2622493T3
(es)
|
2006-02-24 |
2017-07-06 |
Rigel Pharmaceuticals, Inc. |
Composiciones y métodos para la inhibición de la ruta de JAK
|
EP2004632B1
(de)
|
2006-03-30 |
2014-03-12 |
Janssen R&D Ireland |
Hiv-inhibierende 5-amido-substituierte pyrimidine
|
DE602007009508D1
(de)
|
2006-03-30 |
2010-11-11 |
Little Island Co Cork |
Hiv-inhibierende 5-(hydroxymethylen- und aminomethylen) substituierte pyrimidine
|
PE20120006A1
(es)
|
2006-05-15 |
2012-02-02 |
Boehringer Ingelheim Int |
Compuestos derivados de pirimidina como inhibidores de la quinasa aurora
|
BRPI0712346B8
(pt)
|
2006-06-06 |
2021-05-25 |
Janssen R & D Ireland |
processo para produzir pó farmacêutico sólido de tmc125, dispersão sólida e sua formulação farmacêutica
|
EP2526932B1
(de)
|
2006-06-19 |
2017-06-07 |
Alpharma Pharmaceuticals LLC |
Pharmazeutische Zusammensetzung
|
JP2010506833A
(ja)
*
|
2006-10-11 |
2010-03-04 |
アルファーマ,インコーポレイテッド |
医薬組成物
|
JP5464584B2
(ja)
*
|
2006-12-06 |
2014-04-09 |
ヤンセン・アールアンドデイ・アイルランド |
抗hiv化合物の臭化水素酸塩
|
KR20090094084A
(ko)
|
2006-12-29 |
2009-09-03 |
티보텍 파마슈티칼즈 리미티드 |
Hiv를 억제하는 5,6-치환된 피리미딘
|
ES2470570T3
(es)
*
|
2006-12-29 |
2014-06-24 |
Janssen R&D Ireland |
Pirimidinas sustituidas en posición 6 inhibidoras del HIV
|
UA99459C2
(en)
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
US8410124B2
(en)
|
2007-10-18 |
2013-04-02 |
Concert Pharmaceuticals Inc. |
Deuterated etravirine
|
US8623418B2
(en)
|
2007-12-17 |
2014-01-07 |
Alpharma Pharmaceuticals Llc |
Pharmaceutical composition
|
US20100151014A1
(en)
*
|
2008-12-16 |
2010-06-17 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
AU2008338442A1
(en)
*
|
2007-12-17 |
2009-06-25 |
Alpharma Pharmaceuticals, Llc |
Pharmaceutical composition
|
NO2300013T3
(de)
|
2008-05-21 |
2018-02-03 |
|
|
US9273077B2
(en)
|
2008-05-21 |
2016-03-01 |
Ariad Pharmaceuticals, Inc. |
Phosphorus derivatives as kinase inhibitors
|
US8338439B2
(en)
|
2008-06-27 |
2012-12-25 |
Celgene Avilomics Research, Inc. |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
US11351168B1
(en)
|
2008-06-27 |
2022-06-07 |
Celgene Car Llc |
2,4-disubstituted pyrimidines useful as kinase inhibitors
|
KR20110025224A
(ko)
|
2008-06-27 |
2011-03-09 |
아빌라 테라퓨틱스, 인크. |
헤테로아릴 화합물 및 이의 용도
|
US20100137313A1
(en)
*
|
2008-10-03 |
2010-06-03 |
Astrazeneca Ab |
Heterocyclic derivatives and methods of use thereof
|
US20110071158A1
(en)
*
|
2009-03-18 |
2011-03-24 |
Boehringer Ingelheim International Gmbh |
New compounds
|
BRPI1012666B8
(pt)
|
2009-03-30 |
2021-05-25 |
Janssen R&D Ireland |
cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso
|
ES2659725T3
(es)
|
2009-05-05 |
2018-03-19 |
Dana-Farber Cancer Institute, Inc. |
Inhibidores de EGFR y procedimiento de tratamiento de trastornos
|
WO2010131118A2
(en)
*
|
2009-05-12 |
2010-11-18 |
Pliva Hrvatska D.O.O. |
Polymorphs of etravirine and processes for preparation thereof
|
WO2010150279A2
(en)
|
2009-06-22 |
2010-12-29 |
Emcure Pharmaceuticals Limited |
Process for synthesis of diarylpyrimidine non-nucleoside reverse transcriptase inhibitor
|
WO2011017079A1
(en)
|
2009-07-27 |
2011-02-10 |
Teva Pharmaceutical Industries Ltd. |
Process for the preparation and purification of etravirine and intermediates thereof
|
GR1007010B
(el)
|
2009-10-08 |
2010-10-07 |
Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), |
Ινσουλινοειδη πεπτιδια
|
SG185641A1
(en)
|
2010-06-04 |
2012-12-28 |
Hoffmann La Roche |
Aminopyrimidine derivatives as lrrk2 modulators
|
WO2012001695A1
(en)
|
2010-06-28 |
2012-01-05 |
Hetero Research Foundation |
A process for etra virine intermediate and polymorphs of etravirine
|
ES2617763T3
(es)
|
2010-08-10 |
2017-06-19 |
Celgene Avilomics Research, Inc. |
Sal de besilato de un inhibidor de BTK
|
EA201390421A1
(ru)
|
2010-09-22 |
2013-09-30 |
Арена Фармасьютикалз, Инк. |
Модуляторы рецептора gpr119 и лечение связанных с ним нарушений
|
WO2012061303A1
(en)
|
2010-11-01 |
2012-05-10 |
Avila Therapeutics, Inc. |
Heteroaryl compounds and uses thereof
|
WO2012061299A1
(en)
|
2010-11-01 |
2012-05-10 |
Avila Therapeutics, Inc. |
Heterocyclic compounds and uses thereof
|
JP5957003B2
(ja)
|
2010-11-10 |
2016-07-27 |
セルジーン アヴィロミクス リサーチ, インコーポレイテッド |
変異体選択的egfr阻害剤およびその使用
|
EP2638031B9
(de)
|
2010-11-10 |
2020-01-08 |
Genentech, Inc. |
Pyrazolaminopyrimidinderivate als lrrk2-modulatoren
|
EP2702045B1
(de)
|
2011-04-26 |
2017-10-18 |
Mylan Laboratories Ltd. |
Neues verfahren zur herstellung von etravirin
|
CN103501612B
(zh)
|
2011-05-04 |
2017-03-29 |
阿里亚德医药股份有限公司 |
抑制表皮生长因子受体导致的癌症中细胞增殖的化合物
|
WO2012170647A1
(en)
*
|
2011-06-09 |
2012-12-13 |
Assia Chemical Industriew Ltd. |
Process for the preparation of etravirine and intermediates in the synthesis thereof
|
JP5993010B2
(ja)
|
2011-08-23 |
2016-09-14 |
エンドゥ ファーマシューティカルズ,インコーポレイティド |
ピリミド−ピリダジノン化合物及びその使用
|
US20130123498A1
(en)
|
2011-10-19 |
2013-05-16 |
Maja Sepelj MAJER |
Process for the preparation of etravirine and intermediates in the synthesis thereof
|
EP2770830A4
(de)
|
2011-10-28 |
2015-05-27 |
Celgene Avilomics Res Inc |
Verfahren zur behandlung einer bruton-tyrosinkinase-erkrankung oder -störung
|
US8703786B2
(en)
*
|
2011-12-07 |
2014-04-22 |
Texas Southern University |
Etravirine formulations and uses thereof
|
DK2825042T3
(en)
|
2012-03-15 |
2018-11-26 |
Celgene Car Llc |
SALTS OF THE CHINASE INHIBITOR OF THE EPIDERMAL GROWTH FACTOR RECEPTOR
|
BR112014022789B1
(pt)
|
2012-03-15 |
2022-04-19 |
Celgene Car Llc |
Formas sólidas de um inibidor de quinase de receptor do fator de crescimento epidérmico, composição farmacêutica e usos do mesmo
|
AU2013204563B2
(en)
|
2012-05-05 |
2016-05-19 |
Takeda Pharmaceutical Company Limited |
Compounds for inhibiting cell proliferation in EGFR-driven cancers
|
US20150336900A1
(en)
*
|
2012-10-29 |
2015-11-26 |
Biophore India Pharmaceuticals Pvt. Ltd. |
Process for the Synthesis of Etravirine and Its Intermediates
|
WO2014072419A1
(en)
|
2012-11-08 |
2014-05-15 |
Universiteit Antwerpen |
Novel anti-hiv compounds
|
WO2014100748A1
(en)
|
2012-12-21 |
2014-06-26 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
RU2015126505A
(ru)
|
2012-12-21 |
2017-01-27 |
Верликс Фарма Инк. |
Применение и способы лечения заболеваний и патологических состояний печени
|
US9561228B2
(en)
|
2013-02-08 |
2017-02-07 |
Celgene Avilomics Research, Inc. |
ERK inhibitors and uses thereof
|
US9611283B1
(en)
|
2013-04-10 |
2017-04-04 |
Ariad Pharmaceuticals, Inc. |
Methods for inhibiting cell proliferation in ALK-driven cancers
|
US9492471B2
(en)
|
2013-08-27 |
2016-11-15 |
Celgene Avilomics Research, Inc. |
Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
|
US9415049B2
(en)
|
2013-12-20 |
2016-08-16 |
Celgene Avilomics Research, Inc. |
Heteroaryl compounds and uses thereof
|
DK3179858T3
(da)
|
2014-08-13 |
2019-07-22 |
Celgene Car Llc |
Forme og sammensætninger af en ERK-inhibitor
|
KR102595163B1
(ko)
|
2015-01-06 |
2023-10-30 |
아레나 파마슈티칼스, 인크. |
S1p1 수용체와 관련된 상태의 치료 방법
|
CN104926829A
(zh)
*
|
2015-06-08 |
2015-09-23 |
山东大学 |
一种噻吩并嘧啶类衍生物及其制备方法和应用
|
WO2016209809A1
(en)
|
2015-06-22 |
2016-12-29 |
Arena Pharmaceuticals, Inc. |
Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(compound1) for use in sipi receptor-associated disorders
|
CN110066273A
(zh)
*
|
2019-06-05 |
2019-07-30 |
山东大学 |
一种含三氮唑环的单芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用
|
US11529350B2
(en)
|
2019-07-03 |
2022-12-20 |
Sumitomo Pharma Oncology, Inc. |
Tyrosine kinase non-receptor 1 (TNK1) inhibitors and uses thereof
|
CN111217833B
(zh)
*
|
2020-02-21 |
2021-03-16 |
山东大学 |
噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
|
CN111875548A
(zh)
*
|
2020-07-16 |
2020-11-03 |
山东大学 |
一种5位芳环取代的二芳基嘧啶类衍生物及其制备方法与应用
|